your catalyst to a lucrative business n.
Skip this Video
Loading SlideShow in 5 Seconds..
Point of Care (POC) Diagnostics Market Size, Share, Growth and Forecast to 2020 - Hexa Research PowerPoint Presentation
Download Presentation
Point of Care (POC) Diagnostics Market Size, Share, Growth and Forecast to 2020 - Hexa Research

Point of Care (POC) Diagnostics Market Size, Share, Growth and Forecast to 2020 - Hexa Research

71 Views Download Presentation
Download Presentation

Point of Care (POC) Diagnostics Market Size, Share, Growth and Forecast to 2020 - Hexa Research

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Your Catalyst To a Lucrative Business Point of Care (POC) Diagnostics Market Analysis, Size, Share, Growth and Forecast to 2020 | Hexa Research “Growing popularity of EMR (electronic medical record) and PACS (picture archiving and communication systems) has a positive impact on Point of Care (POC) Diagnostics Market demand.” The Global Point Of Care Diagnostics Market is driven by technological improvements and introduction of sophisticated medical solutions. A host of healthcare establishments are gradually taking to point of care tests and diagnostics solutions for greater efficiency. Growing popularity of EMR (electronic medical record) and PACS (picture archiving and communication systems) has a positive impact on market demand. Other industry drivers are governmental support, surging healthcare investments, growing geriatric population, and widespread adoption of home based POC devices. When medical diagnostics tests are carried out at the place of patient care, it is known as bedside testing or POCT (point-of-care-testing). New product development is a vital factor that may contribute significantly to market growth during the forecast period (2012 to 2020). Browse Details of Report@ Follow Us:

  2. Your Catalyst To a Lucrative Business Products, end users, and regions are the parameters based on which the global point of care (POC) diagnostics industry is categorized. As per products, the segments are blood gas/electrolytes, fertility, cardiac markers, OTC & rapid diagnostic tests, infectious diseases, coagulation, drug abuse testing, hospital glucose testing, decentralized clinical chemistry, hematology, and urinalysis. Products also include primary care systems, such as HbA1c tests and lipid profiling. Hospital glucose testing holds the highest market share. Factors that propel this segment are high incidence of diabetes and the growing necessity for glucose analysis on a regular basis. The OTC & rapid diagnostic tests market may expand robustly over the forecast period because of the “self diagnosis” trend. People nowadays are highly aware of the importance of early disease diagnosis for on-time & instant disease treatment. Based on end users, the global industry is divided into laboratories, hospitals, clinics, assisted living healthcare facilities, homes, and others. Hospitals & clinics generate highest revenues in the overall market. Diagnostic tests are mostly conducted in clinics and in hospitals. As a result, most of these healthcare centers have begun expanding their POC diagnostic facilities. Geographically, the worldwide Point Of Care Diagnostics Market is categorized into Asia Pacific, Europe, North America, and Rest of the World (RoW). North America is the largest regional industry. High degree of patient awareness, encouraging government initiatives, and substantial investments in medical infrastructure are prominent regional drivers. It is however, expected that Asia Pacific will register the highest growth rate over the forecast period. This attributes to improvements in healthcare infrastructure in emerging countries, such as India and China. Companies operating in the global Point Of Care Diagnostics Market continuously strive towards capturing higher market shares. They invest robustly in R&D and product innovations. Prominent market competitors are Trinity Biotech PLC, Danaher Corporation, Siemens Healthcare, Roche Diagnostics, and Becton Dickinson and Company. In September 2016, Novartis launched the NijiTM System and Total IgE Test, a POC diagnostic tool. By using just a droplet or two of finer stick blood, this device delivers Immunoglobulin E (IgE) levels in a matter of twelve minutes. This test caters to immediate in-office diagnosis of allergies associated with IgE levels. The availability of such tests in the offices of healthcare providers leads to reduced time for consultation, diagnosis, prognosis, and disease treatment. This in turn leads to better patient outcomes. Browse Related Category Market Reports @ Follow Us:

  3. Your Catalyst To a Lucrative Business Table of Content of Point of Care (POC) Diagnostics Market Chapter 1. Executive Summary 1.1. Point of Care Diagnostics – Industry Summary and Critical Success Factors (CSFs) Chapter 2. Point of Care Diagnostics Industry Outlook 2.1. Market Segmentation 2.2. Market Size and Growth Prospects 2.3. Point of Care Diagnostics Market Dynamics 2.4. Key Opportunities Prioritized 2.5. Industry Analysis - Porter's 2.6. Point of Care Diagnostics - Company Market Share Analysis 2.7. Point of Care Diagnostics Market PESTEL Analysis, 2012 Chapter 3. Point of Care Diagnostics Product Outlook 3.1. Blood Gas/Electrolytes (Centralized and Decentralized) 3.2. Infectious Diseases 3.3. Hospital Glucose Testing 3.4. Cardiac Markers 3.5. Hematology 3.6. Coagulation 3.7. Primary Care Systems (Lipid Profiling and HbA1c Tests) 3.8. Decentralized Clinical Chemistry 3.9. Urinalysis 3.10. Drug Abuse Testing 3.11. Fertility 3.12. OTC and Rapid Diagnostic Tests Chapter 4. Point of Care Diagnostics End User Outlook 4.1. Hospitals 4.2. Assisted Living Healthcare Facilities 4.3. Laboratories 4.4. Home 4.5. Clinics 4.6. Others Follow Us:

  4. Your Catalyst To a Lucrative Business Chapter 5. Point of Care Diagnostics Regional Outlook 5.1. North America 5.2. Europe 5.3. Asia Pacific 5.4. RoW Chapter 6. Point of Care Diagnostics Competitive landscape 6.1. Roche Diagnostics 6.1.1 Company Overview 6.1.2 Financial Performance 6.1.3 Product Benchmarking 6.1.4 Strategic Initiatives 6.2 Abbott Laboratories 6.2.1 Company Overview 6.2.2 Financial Performance 6.2.3 Product Benchmarking 6.2.4 Strategic Initiatives 6.3 Siemens Healthcare 6.3.1 Company Overview 6.3.2 Financial Performance 6.3.3 Product Benchmarking 6.3.4 Strategic Initiatives 6.4 Beckman Coulter Inc. 6.4.1 Company Overview 6.4.2 Financial Performance 6.4.3 Product Benchmarking 6.4.4 Strategic Initiatives 6.5 Becton Dickinson and Company 6.5.1 Company Overview 6.5.2 Financial Performance 6.5.3 Product Benchmarking 6.5.4 Strategic Initiatives 6.6 bioMérieux 6.6.1 Company Overview 6.6.2 Financial Performance 6.6.3 Product Benchmarking Follow Us:

  5. Your Catalyst To a Lucrative Business 6.6.4 Strategic Initiatives 6.7 Johnson and Johnson 6.7.1 Company Overview 6.7.2 Financial Performance 6.7.3 Product Benchmarking 6.7.4 Strategic Initiatives 6.8 Abaxis Inc. 6.8.1 Company Overview 6.8.2 Financial Performance 6.8.3 Product Benchmarking 6.8.4 Strategic Initiatives 6.9 Alere Inc. 6.9.1 Company Overview 6.9.2 Financial Performance 6.9.3 Product Benchmarking 6.9.4 Strategic Initiatives 6.10 Danaher Corporation 6.10.1 Company Overview 6.10.2 Financial Performance 6.10.3 Product Benchmarking 6.10.4 Strategic Initiatives 6.11 Qiagen (AmniSure) 6.11.1 Company Overview 6.11.2 Financial Performance 6.11.3 Product Benchmarking 6.11.4 Strategic Initiatives 6.12 Spectral Diagnostics 6.12.1 Company Overview 6.12.2 Financial Performance 6.12.3 Product Benchmarking 6.12.4 Strategic Initiatives 6.13 Church & Dwight Co. Inc. 6.13.1 Company Overview 6.13.2 Financial Performance 6.13.3 Product Benchmarking 6.13.4 Strategic Initiatives Follow Us:

  6. Your Catalyst To a Lucrative Business 6.14 Trinity Biotech PLC 6.14.1 Company Overview 6.14.2 Financial Performance 6.14.3 Product Benchmarking 6.14.4 Strategic Initiatives 6.15 Nipro Diagnostics Inc. 6.15.1 Company Overview 6.15.2 Financial Performance 6.15.3 Product Benchmarking 6.15.4 Strategic Initiatives 6.16 Hemocue AB 6.16.1 Company Overview 6.16.2 Financial Performance 6.16.3 Product Benchmarking 6.16.4 Strategic Initiatives 6.17 Nova Biomedical 6.17.1 Company Overview 6.17.2 Financial Performance 6.17.3 Product Benchmarking 6.17.4 Strategic Initiatives 6.18 Pharmatech Inc. 6.18.1 Company Overview 6.18.2 Financial Performance 6.18.3 Product Benchmarking 6.18.4 Strategic Initiatives 6.19 International Technidyne Corporation (ITC) 6.19.1 Company Overview 6.19.2 Financial Performance 6.19.3 Product Benchmarking 6.19.4 Strategic Initiatives 6.20 Quidel Corporation 6.20.1 Company Overview 6.20.2 Financial Performance 6.20.3 Product Benchmarking 6.20.4 Strategic Initiatives 6.21 Sekisui Diagnostics Follow Us:

  7. Your Catalyst To a Lucrative Business 6.21.1 Company Overview 6.21.2 Financial Performance 6.21.3 Product Benchmarking 6.21.4 Strategic Initiatives 6.22 OraSure Technologies Inc. 6.22.1 Company Overview 6.22.2 Financial Performance 6.22.3 Product Benchmarking 6.22.4 Strategic Initiatives Chapter 7. Methodology and Scope 7.1. Research Methodology 7.2. Research Scope & Assumption 7.3. List of Data Sources Follow Us:

  8. Your Catalyst To a Lucrative Business About Us: Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives. Contact Us: Ryan Shaw Hexa Research Felton Office Plaza 6265 Highway 9 Felton, California 95018 United States Phone: +1-800-489-3075 Email: Website - Visit Our Blog - Follow Us: